Everest Organics advances after filing first US DMF

04 Sep 2019

Everest Organics is currently trading at Rs. 224.50, up by 13.20 points or 6.25% from its previous closing of Rs. 211.30 on the BSE.

The scrip opened at Rs. 220.90 and has touched a high and low of Rs. 229.50 and Rs. 210.00 respectively. So far 4131 shares were traded on the counter.

The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 245.00 on 28-Aug-2019 and a 52 week low of Rs. 57.15 on 29-Oct-2018.

Last one week high and low of the scrip stood at Rs. 242.00 and Rs. 203.30 respectively. The current market cap of the company is Rs. 180.00 crore.

The promoters holding in the company stood at 73.28%, while Institutions and Non-Institutions held 0.03% and 26.69% respectively.

Everest Organics has submitted the first US DMF for Esomeprazole Magnesium API.

Ever since the successful USFDA approval received for its manufacturing facility, the company has placed a separate focus to strengthen its presence in regulatory markets. With the first filing of US-DMF for Esomeprazole Magnesium, the company focuses to increase presence in the US market for substantial revenue generation.

Everest Organics is a fast growing API and Bulk drug manufacturing company with world class facility and it is committed to manufacturing excellent quality products and customer service.

Related Everest Organics Ltd. Links:

Everest Organics Share Price

262.85 3.40 (1.31%) Oct 19, 18:01
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 483.60
Dr. Reddys Lab 5051.45
Lupin 1013.90
Piramal Enterprises 1322.90
Cadila Healthcare 422.50
View more..
Sensex vs Everest Organics
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback